Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients with Relapsed or Refractory Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients with Relapsed or Refractory Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMGS-001 (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors IMMUNOGENESIS

Most Recent Events

  • 30 May 2025 According to an IMMUNOGENESIS media release, trial in progress poster form this trial was presented at the ASCO 2025 meeting. The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling.
  • 20 Mar 2025 According to an IMMUNOGENESIS media release, company will present preliminary data on enrolled subjects at Innovation Track of the 2025 NeauxCancer Oncology Conference in New Orleans
  • 28 Sep 2023 According to an IMMUNOGENESIS media release, first patient has been dosed at The University of Texas MD Anderson Cancer Center in Houston, Texas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top